DE3473143D1 - Anticonvulsant sulfamate derivatives - Google Patents

Anticonvulsant sulfamate derivatives

Info

Publication number
DE3473143D1
DE3473143D1 DE8484306512T DE3473143T DE3473143D1 DE 3473143 D1 DE3473143 D1 DE 3473143D1 DE 8484306512 T DE8484306512 T DE 8484306512T DE 3473143 T DE3473143 T DE 3473143T DE 3473143 D1 DE3473143 D1 DE 3473143D1
Authority
DE
Germany
Prior art keywords
sub
sulfamate derivatives
anticonvulsant sulfamate
anticonvulsant
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8484306512T
Other languages
German (de)
English (en)
Inventor
Bruce Eliot Maryanoff
Joseph Francis Gardocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
McNeilab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24134409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3473143(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by McNeilab Inc filed Critical McNeilab Inc
Application granted granted Critical
Publication of DE3473143D1 publication Critical patent/DE3473143D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE8484306512T 1983-09-26 1984-09-25 Anticonvulsant sulfamate derivatives Expired DE3473143D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,475 US4513006A (en) 1983-09-26 1983-09-26 Anticonvulsant sulfamate derivatives

Publications (1)

Publication Number Publication Date
DE3473143D1 true DE3473143D1 (de) 1988-09-08

Family

ID=24134409

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484306512T Expired DE3473143D1 (de) 1983-09-26 1984-09-25 Anticonvulsant sulfamate derivatives

Country Status (18)

Country Link
US (1) US4513006A (enExample)
EP (1) EP0138441B1 (enExample)
JP (2) JPS60109558A (enExample)
KR (1) KR920001775B1 (enExample)
AT (1) ATE36149T1 (enExample)
AU (1) AU564842B2 (enExample)
CA (1) CA1241951A (enExample)
DE (1) DE3473143D1 (enExample)
DK (3) DK165004C (enExample)
ES (1) ES8602634A1 (enExample)
FI (1) FI79095C (enExample)
HU (1) HU194540B (enExample)
IE (1) IE57684B1 (enExample)
MX (1) MX9202630A (enExample)
NL (1) NL990025I2 (enExample)
NO (2) NO170280C (enExample)
NZ (1) NZ209494A (enExample)
ZA (1) ZA847550B (enExample)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
PT94305B (pt) * 1989-06-12 1997-02-28 Robins Co Inc A H Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6903084B2 (en) 1991-08-28 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
NZ277725A (en) * 1993-12-23 1998-04-27 Ortho Pharma Corp Pseudofructopyranose sulphamate derivatives, preparation and pharmaceutical compositions thereof
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
KR970027051A (ko) * 1995-11-02 1997-06-24 조규향 카바모일기를 포함하는 신규한 설파메이트 화합물
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
DE69706195T2 (de) * 1996-06-28 2002-05-02 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive derivate zur behandlung von psoriasis
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
CA2258893C (en) * 1996-06-28 2005-06-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
WO1998000124A1 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
ATE226071T1 (de) * 1996-10-08 2002-11-15 Ortho Mcneil Pharm Inc Antikonvulsive derivate zur behandlung von neuropathischem schmerz
JP3744089B2 (ja) * 1996-12-02 2006-02-08 富士電機ホールディングス株式会社 マグネトロンスパッタ成膜装置および成膜方法
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
CA2348017C (en) * 1998-10-20 2005-07-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse
US6472370B1 (en) * 1998-11-17 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating post traumatic stress disorder
AU771388B2 (en) * 1999-01-19 2004-03-18 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cluster headaches
AU3582600A (en) * 1999-01-21 2000-08-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating transformed migraine
KR100664618B1 (ko) * 1999-02-01 2007-01-04 오르토-맥네일 파마슈티칼, 인코퍼레이티드 신경성 대식증 치료용으로의 항경련성 유도체의 용도
JP2002536328A (ja) * 1999-02-08 2002-10-29 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 自閉症の処置に有効な抗痙攣剤誘導体
WO2000048549A2 (en) * 1999-02-17 2000-08-24 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating essential tremor
MXPA01008537A (es) 1999-02-24 2005-02-17 Univ Cincinnati Uso de derivados de sulfamato para tratar desordenes de control de impulso.
WO2000061137A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
CA2369230A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
NZ514812A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering blood pressure
MXPA01011014A (es) * 1999-04-30 2003-06-30 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de dependencia de cocaina.
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
MXPA01012187A (es) * 1999-05-28 2002-06-21 Jeffrey Berlant Compuestos y metodos para el tratamiento del trastorno por estres postraumatico.
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
ATE369126T1 (de) 1999-06-14 2007-08-15 Vivus Inc Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
WO2001013904A2 (en) * 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US7335650B2 (en) * 2000-01-14 2008-02-26 Sterix Limited Composition
SE0000601D0 (sv) 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
CN101404993A (zh) * 2000-07-07 2009-04-08 奥索-麦克尼尔药品公司 用于预防ii型糖尿病和x综合征的发展的抗惊厥剂衍生物
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
EP1309325A1 (en) * 2000-08-02 2003-05-14 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
AU2002253838B2 (en) 2000-10-30 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
EP1345602B1 (en) * 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
CN1477976A (zh) 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与醛糖还原酶抑制剂的组合
KR20030059290A (ko) 2000-11-30 2003-07-07 화이자 프로덕츠 인코포레이티드 Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물
PT1471871E (pt) * 2001-02-02 2007-06-05 Ortho Mcneil Pharm Inc Tratamento de disfunção neurológica compreendendo sulfamatos de frutopiranose e eritropoietina
JP2004331502A (ja) * 2001-06-18 2004-11-25 Ortho Mcneil Pharmaceut Inc 視神経細胞保護剤
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
UA78211C2 (en) * 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US20030092636A1 (en) * 2001-11-06 2003-05-15 Silberstein Stephen D. Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
KR101008326B1 (ko) * 2002-02-26 2011-01-13 오르토-맥네일 파마슈티칼, 인코퍼레이티드 항경련제 유도체 및 항-편두통제를 포함하는 편두통치료를 위한 공-요법
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US7060725B2 (en) * 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
MXPA04011203A (es) * 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1515703A1 (en) * 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
WO2004024163A1 (en) * 2002-09-13 2004-03-25 Motac Neuroscience Limited Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7196209B2 (en) * 2002-10-31 2007-03-27 Ortho-Mcneil Pharmaceutical, Inc. Continuous process for the preparation of fructopyranose sulfamate derivatives
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
RU2005122008A (ru) * 2002-12-13 2006-02-10 Цилаг Аг (Ch) Препараты с контролируемым высвобождением, содержащие трамадол и топирамат
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
UA81657C2 (ru) * 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Способ получения противосудорожных производных топирамата
WO2004089965A2 (en) * 2003-04-07 2004-10-21 Cipla Ltd Topiramate and processes for the preparation thereof
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
WO2004108732A1 (en) * 2003-05-12 2004-12-16 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF 2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ß-D-FRUCTOPYRANOSE SULFAMATE
RU2005135454A (ru) * 2003-05-16 2006-06-27 Пфайзер Продактс Инк. (Us) Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
MXPA06001548A (es) * 2003-08-06 2006-09-04 Johnson & Johnson Suministro uniforme de topiramato durante un periodo prolongado con formulaciones de dispersion.
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
EP1673064A1 (en) * 2003-08-28 2006-06-28 Sandoz AG Pharmaceutical composition comprising anticonvulsant with taste mask coating
US20050069587A1 (en) * 2003-09-02 2005-03-31 Modi Nishit Bachulal Novel drug compositions and dosage forms of topiramate
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
AU2004312082A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
CA2553291A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
US20050203287A1 (en) * 2004-03-11 2005-09-15 Chandrasekhar Batchu Process for the preparation of sulfamate derivatives
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1627881B1 (en) * 2004-08-19 2006-10-04 Helm AG Process for the preparation of topiramate
MY142329A (en) * 2004-08-24 2010-11-15 Janssen Pharmaceutica Nv Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
WO2006127184A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
WO2006125774A1 (en) * 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US7851498B2 (en) * 2005-09-23 2010-12-14 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
CN101312726A (zh) * 2005-09-23 2008-11-26 詹森药业有限公司 六氢-环庚三烯并吡唑大麻素调节剂
US7790718B2 (en) 2005-09-23 2010-09-07 Janssen Pharmaceutica Nv Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
WO2007041195A2 (en) * 2005-09-29 2007-04-12 Janssen Pharmaceutica N.V. Macroheterocylic compounds as kinase inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
EP1979593B1 (en) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
WO2007095513A1 (en) * 2006-02-14 2007-08-23 Janssen Pharmaceutica, Nv Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
TW200738669A (en) * 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
WO2007099388A1 (en) * 2006-03-01 2007-09-07 Glade Organics Private Limited An improved process for the manufacture of topiramate
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007106400A2 (en) * 2006-03-10 2007-09-20 Janssen Pharmaceutica, N.V. Pyridine-containing macroheterocylic compounds as kinase inhibitors
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
TW200812574A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2008010231A2 (en) * 2006-05-26 2008-01-24 Alembic Limited A process for the purification of topiramate
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034040A1 (en) * 2006-09-15 2008-03-20 Regents Of The University Of Minnesota Topiramate compositions and methods for their use
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TWI504419B (zh) 2006-11-09 2015-10-21 Orexigen Therapeutics Inc 層狀醫藥調配物
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
CN102114002B (zh) 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
AR070949A1 (es) * 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
JP2011515464A (ja) * 2008-03-26 2011-05-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾ縮合されたヘテロアリールスルファマート及びｎ−（（（２ｓ）−６−クロロ−２，３−ジヒドロ−ｌ，４−ベンゾジオキシン−２イル）メチル−スルファミドの調製プロセス
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20120121692A1 (en) * 2009-05-08 2012-05-17 Shandong University Compounds and compositions comprising cdk inhibitors and methods for treating cancer
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
EP2367836B8 (en) 2010-02-05 2015-09-02 Scinopharm Taiwan Ltd. Process for the preparation and purification of topiramate
EA201492175A1 (ru) 2012-06-06 2015-10-30 Орексиджен Терапьютикс, Инк. Способы лечения избыточного веса и ожирения
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
HK1213473A1 (zh) 2013-03-15 2016-07-08 阿普雷奇亚制药有限责任公司 托吡酯的快速分散劑型
CN103910770B (zh) * 2014-03-14 2017-01-04 天津南开允公医药科技有限公司 一种托吡酯的制备方法以及该方法中所涉及的中间体晶型及其制备方法
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997585A (en) * 1974-12-30 1976-12-14 Ortho Pharmaceutical Corporation Aliphatic sulfamates

Also Published As

Publication number Publication date
MX9202630A (es) 1992-06-30
FI843765L (fi) 1985-03-27
DK165003B (da) 1992-09-28
EP0138441A3 (en) 1986-08-27
NZ209494A (en) 1987-03-06
DK198191D0 (da) 1991-12-09
HU194540B (en) 1988-02-29
FI79095B (fi) 1989-07-31
DK165004B (da) 1992-09-28
NO843836L (no) 1985-03-27
NO170280B (no) 1992-06-22
DK165004C (da) 1993-02-08
EP0138441A2 (en) 1985-04-24
CA1241951A (en) 1988-09-13
NL990025I1 (nl) 1999-11-01
ES536225A0 (es) 1985-11-16
AU3350484A (en) 1985-04-04
FI843765A0 (fi) 1984-09-25
NO1997004I1 (no) 1997-05-09
JPH055824B2 (enExample) 1993-01-25
ATE36149T1 (de) 1988-08-15
KR920001775B1 (ko) 1992-03-02
DK198291A (da) 1991-12-09
EP0138441B1 (en) 1988-08-03
DK165003C (da) 1993-02-08
FI79095C (fi) 1989-11-10
US4513006A (en) 1985-04-23
DK198191A (da) 1991-12-09
NO170280C (no) 1992-09-30
JPS60109558A (ja) 1985-06-15
IE842444L (en) 1985-03-26
NL990025I2 (nl) 1999-12-01
JPH05331132A (ja) 1993-12-14
AU564842B2 (en) 1987-08-27
HUT36784A (en) 1985-10-28
ZA847550B (en) 1986-05-28
DK457784A (da) 1985-03-27
IE57684B1 (en) 1993-02-24
DK198291D0 (da) 1991-12-09
DK173923B1 (da) 2002-02-18
KR850002264A (ko) 1985-05-10
ES8602634A1 (es) 1985-11-16
DK457784D0 (da) 1984-09-25

Similar Documents

Publication Publication Date Title
DE3473143D1 (de) Anticonvulsant sulfamate derivatives
CA2152486A1 (en) Anticonvulsant sorbopyranose sulfamates
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
ES542322A0 (es) Un procedimiento para la preparacion de derivados de la 2 pirimidinil-1-piperazina
DK0659174T3 (da) Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler
ATE65500T1 (de) Arylthioalkylphenylcarbonsaeuren, diese enthaltende zusammensetzungen und deren verwendung.
ES8801242A1 (es) Un procedimiento para la preparacion de metanosulfonatos de dioxolano.
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
ES539123A0 (es) Un compuesto de 3-indolcarboxamida
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
HUT76276A (en) 3-substituted 1-arylindole compounds, pharmaceutical compositions containing them and their use
ES8605472A1 (es) Procedimiento para la preparacion de derivados de 1-(n-(a- amino-a-metilacetil)-aminofenil)-2-amino-propanona
IT1179601B (it) Composto e composizione farmaceutica ad azione anticonvulsiva particolarmente per il trattamento della epilessia
ATE44741T1 (de) 2-(n-substituierte guanidino)-4heteroarylthiazole als mittel gegen geschwuere.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: TOPIRAMAT; REGISTRATION NO/DATE: 35027.00.00, 35027.01.00, 35027.02.00, 35027.03.00, 35027.04.00, 35027.05.00; 19980720

Spc suppl protection certif: 198 75 035

Filing date: 19980819

V457 Spc granted

Free format text: PRODUCT NAME: TOPIRAMAT; REGISTRATION NO/DATE: 35027.00.00, 35027.01.00, 35027.02.00, 35027.03.00, 35027.04.00, 35027.05.00; 19980720

Spc suppl protection certif: 198 75 035

Filing date: 19980819

V464 Spc expired

Free format text: PRODUCT NAME: TOPIRAMAT; REGISTRATION NO/DATE: 35027.00.00, 35027.01.00, 35027.02.00, 35027.03.00, 35027.04.00, 35027.05.00; 19980720

Spc suppl protection certif: 198 75 035

Filing date: 19980819